Bridge Capture™ Technology Enhances Liquid Biopsy Sensitivity for Colorectal Cancer

Enhancing Cancer Detection with Bridge Capture™ Technology



In a significant step towards advancing cancer diagnostics, Genomill Health, a pioneering biotechnology firm, recently announced impressive results from a clinical pilot study published in Scientific Reports. This study focused on the efficacy of their innovative Bridge Capture™ technology, which is designed for sensitive liquid biopsy applications in metastatic colorectal cancer patients. The outcomes reveal the technology’s capability to detect crucial genetic mutations present in cell-free DNA extracted from blood samples.

The study's collaboration with a team led by Professor Ari Ristimäki from the Helsinki University Hospital highlighted Bridge Capture™'s ability to match the sensitivity of the established digital droplet PCR (ddPCR), regarded as the gold standard for mutation detection. What sets this technology apart is its scalability and cost-effectiveness, making it a viable option for decentralized next-generation sequencing (NGS) tests. This is particularly noteworthy given the increasing need for accessible and efficient cancer testing solutions.

Professor Ristimäki praised Bridge Capture™ for integrating high sensitivity with user-friendly and economical processes. He emphasized that this technology can vastly improve the way liquid biopsies are utilized in monitoring treatment responses and disease progression in patients. The ability to not just detect, but track mutations over time presents a powerful tool for clinicians aiming to monitor patients' conditions effectively.

Dr. Simona Adamusová, a doctoral student and co-first author of the study, remarked on the significance of achieving or exceeding gold standard methods in mutation identification. She stated, “The capability to monitor changes over time is a powerful instrument in tracking cancer progression and potential relapses.” This sentiment was echoed by Manu Tamminen, the co-founder and Managing Director of Genomill, who mentioned the study’s findings as indicative of the technology’s readiness for real-world applications in liquid biopsy workflows.

Bridge Capture™ employs unique technologies based on both circular DNA and linear DNA amplification techniques, positioning it as a trailblazer in NGS library preparation. Juha-Pekka Pursiheimo, the Chief Technology Officer and inventor of this groundbreaking technology noted, “Bridge Capture sets a new standard in NGS library design by utilizing circular single-stranded DNA. This approach not only proves to be more flexible but also more robust than conventional linear libraries. Together with our PCR-free DNA amplification strategies, Genomill is set to revolutionize the NGS library preparation landscape.”

The complete study titled “Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients” is now available for reference in Scientific Reports. This advancement in liquid biopsy technology is anticipated to ease the current barriers posed by costs and infrastructure, enhancing the routine application of liquid biopsies in oncological diagnostics.

For additional information about Genomill Health and their innovative technologies, please visit Genomill. By streamlining cancer diagnostics, the overarching goal remains clear: to make cancer testing not just sophisticated but also widely accessible and effective for patients worldwide.

Conclusion
As the landscape of cancer detection evolves, technologies like Bridge Capture™ stand at the forefront, promising a future where monitoring and profiling genetic mutations becomes part and parcel of routine cancer care, ultimately leading to improved patient outcomes and tailored treatment strategies.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.